CDKN2B-AS1 and cancer: Our experimental and in-silico results are in accordance with recent data showing transcriptional co-activation of ANRIL, p14-ARF, p15-CDKN2B, and p16-CDKN2A in cancers induced by a bidirectional ANRIL–CDKN2A promoter in cell lines of colon cancer [29].